Date: 2017-04-13
Type of information: Establishment of a new subsidiary in the US
Compound: Recordati Rare Diseases Canada
Company: Recordati (Italy)
Therapeutic area: Rare diseases
Type agreement: establishment of a new subsidiary
Action mechanism:
Disease:
Details:
- • On April 13, 2017, Recordati announced the incorporation of its Canadian affiliate, Recordati Rare Diseases Canada.
The company is wholly owned by the Italy-based Recordati Group. It will be the exclusive provider of several treatments, including Carbaglu® (carglumic acid), Cystadane® (betaine anhydrous) and Cosmegen® (dactinomycin) in Canada.
Based in Toronto, Recordati has launched a new website designed to assist Canadians with certain rare diseases across the country. (www.recordatirarediseases.ca)
Financial terms:
Latest news:
Is general: Yes
